前列腺癌发生淋巴转移是患者预后差的主要原因。我们前期研究证实，lncRNA-PMAT1在前列腺癌转移淋巴结中高表达，并促进前列腺癌转移，但具体调控机制尚不清楚。近期预实验结果表明，lncRNA-PMAT1与hnRNPA1结合，激活Wnt/β-catenin信号通路。据此，我们提出lncRNA-PMAT1调控前列腺癌转移的科研假设：lncRNA-PMAT1通过募集hnRNPA1与β-catenin启动子形成三聚体，促进β-catenin表达上调，提高下游转录因子c-Myc表达，参与Wnt/β-catenin/c-Myc信号通路正反馈调节，诱导前列腺癌淋巴转移。本课题拟进一步通过动物实验和染色质免疫共沉淀等技术，阐明lncRNA-PMAT1在介导β-catenin/c-Myc正反馈环路促进前列腺癌淋巴转移中的关键作用及调控机制，为确立lncRNA-PMAT1作为前列腺癌治疗新靶点提供科学依据。

The lymphatic metastasis is the main reason for poor prognosis in prostate cancer. Our previous study found that lncRNA-PMAT1 is highly expressed in metastatic lymph nodes of prostate cancer, but the specific mechanism of lncRNA-PMAT1 regulating lymphatic metastasis is not clear. Recently, our data suggest that lncRNA-PMAT1 is involved in the activation of Wnt / β-catenin signaling pathway by interacting with hnRNPA1. Therefore, we propose a new mechanism of lncRNA-PMAT1 in regulating lymphatic metastasis. LncRNA-PMAT1 activates β-catenin expression by recruiting hnRNPA1 to the β-catenin promoter, which leads to regulate the positive feedback regulation of Wnt/β-catenin/c-Myc signaling pathway and promote lymphatic metastasis of prostate cancer. Furthermore, we will investigate that lncRNA-PMAT1 regulates lymphatic metastasis by recruiting hnRNPA1 by in vitro and in vivo experiments and chromatin immunoprecipitation. The success of this study may reveal new mechanisms for lymphatic metastasis of prostate cancer in the future.